Detalhe da pesquisa
1.
Efficient treatment of colon cancer with codelivery of TRAIL and imatinib by liposomes.
Pharm Dev Technol;
29(1): 52-61, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38230653
2.
ICG-Dimeric Her2-Specific Affibody Conjugates for Tumor Imaging and Photothermal Therapy for Her2-Positive Tumors.
Mol Pharm;
20(1): 427-437, 2023 01 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36315025
3.
Codelivery of TRAIL and Mitomycin C via Liposomes Shows Improved Antitumor Effect on TRAIL-Resistant Tumors.
Mol Pharm;
20(6): 2864-2875, 2023 06 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37134184
4.
Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer.
Molecules;
28(7)2023 Mar 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37049910
5.
Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy.
J Nanobiotechnology;
19(1): 138, 2021 May 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33985511
6.
Conjugation to 10 kDa Linear PEG Extends Serum Half-Life and Preserves the Receptor-Binding Ability of mmTRAIL with Minimal Stimulation of PEG-Specific Antibodies.
Mol Pharm;
14(2): 502-512, 2017 02 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28029256
7.
Preparation and characterization of a novel variant of human tumor necrosis factor-related apoptosis-inducing ligand from the rhesus monkey, Macaca mulatta.
Appl Microbiol Biotechnol;
100(7): 3035-47, 2016 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26610804
8.
[Molecular Cloning, Recombinant Expression and Functional Characterization of the Soluble Tumor Necrosis Factor-related Apoptosis-inducing Ligand for the Macaca mulatta].
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi;
32(3): 605-11, 2015 Jun.
Artigo
em Zh
| MEDLINE
| ID: mdl-26485986
9.
ICG-labeled PD-L1-antagonistic affibody dimer for tumor imaging and enhancement of tumor photothermal-immunotherapy.
Int J Biol Macromol;
269(Pt 2): 132058, 2024 May 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38704065
10.
Development of Clioquinol Platinum(IV) Conjugates as Autophagy-Targeted Antimetastatic Agents.
J Med Chem;
66(5): 3393-3410, 2023 03 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36891739
11.
Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.
J Control Release;
360: 858-871, 2023 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37473808
12.
Production of bioactive, SUMO-modified, and native-like TNF-α of the rhesus monkey, Macaca mulatta, in Escherichia coli.
Appl Microbiol Biotechnol;
93(6): 2345-55, 2012 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22207214
13.
Multi-specific niflumic acid platinum(IV) complexes displaying potent antitumor activities by improving immunity and suppressing angiogenesis besides causing DNA damage.
Dalton Trans;
52(1): 147-158, 2022 Dec 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36472127
14.
Coupling EGFR-Antagonistic Affibody Enhanced Therapeutic Effects of Cisplatin Liposomes in EGFR-expressing Tumor Models.
J Pharm Sci;
111(2): 450-457, 2022 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34547305
15.
Her3-specific affibody mediated tumor targeting delivery of ICG enhanced the photothermal therapy against Her3-positive tumors.
Int J Pharm;
617: 121609, 2022 Apr 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35217073
16.
Fusion of an EGFR-antagonistic affibody enhances the anti-tumor effect of TRAIL to EGFR positive tumors.
Int J Pharm;
620: 121746, 2022 May 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35427745
17.
Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models.
Int J Pharm;
586: 119541, 2020 Aug 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32544521
18.
Modulation of pericytes by a fusion protein comprising of a PDGFRß-antagonistic affibody and TNFα induces tumor vessel normalization and improves chemotherapy.
J Control Release;
302: 63-78, 2019 05 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30930215
19.
Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects.
Theranostics;
8(9): 2459-2476, 2018.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29721092
20.
Enhancing the circulating half-life and the antitumor effects of a tumor-selective cytotoxic peptide by exploiting endogenous serum albumin as a drug carrier.
Int J Pharm;
499(1-2): 195-204, 2016 Feb 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26752086